Mattia Galli/LinkedIn
Dec 19, 2025, 12:07
OCEAN Trial: Rethinking Long-term Anticoagulation after Atrial Fibrillation Ablation
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, posted on LinkedIn:
”Can we drop oral anticoagulant therapy after successful atrial fibrillation ablation?”
Read the full article here.
Title: OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation
Authors: Mattia Galli, Beatrice Simeone, Sebastiano Sciarretta
Stay updated with Hemostasis Today.
Anticoagulation
Atrial Fibrillation
Atrial Fibrillation Ablation
Beatrice Simeone
Cardiology
ESC
European Heart Journal
European Society of Cardiology
Health
Heart Health
Hematology
Hemostasis
Hemostasis Today
Long-term Anticoagulation
Mattia Galli
Medicine
OCEAN Trial
Sapienza University of Rome
Sebastiano Sciarretta
thrombosis
-
Feb 20, 2026, 17:27Sheharyar Raza: Examining Guideline Discordance in Evidence-Based Apheresis Recommendations
-
Feb 20, 2026, 17:23Barbara Mora: Newly Discovered EPO Gene Intronic Variant as a Cause of Congenital Erythrocytosis
-
Feb 20, 2026, 16:48Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
-
Feb 20, 2026, 16:41Uche Kennedy: Hemophilia Care Needs Systems Reform, Not Short-Term Fixes
-
Feb 20, 2026, 16:33Sonal Sonu: Real Clinical Maturity is Knowing When to Stop
-
Feb 20, 2026, 16:27Clear Recommendations for Daily Management and Family Support in Hemophilia A – WFH
-
Feb 20, 2026, 16:24Emerging Advances in Transfusion Medicine from AI to Genomic Blood Typing – ASH
-
Feb 20, 2026, 15:56Alan Nurden: Highlighting the Role of Activated Platelets in Heart and Kidney Complications of Diabetes
-
Feb 20, 2026, 15:51Domenico Girelli: Continuing Commitment to Rare Disease Research